1616599-01-9

Upstream product

• 1616598-91-4 {5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}methanol 
• 1616598-88-9 C₂₀H₂₃N₅O₅ 
• 1616598-92-5 C₁₁H₁₁ClN₄O₃ 
• 61948-60-5 2,4-dichloro-8-methoxy-quinazoline 
• 62484-14-4 8-methoxyquinazoline-2,4-diol 
• 3177-80-8 2-amino-3-methoxybenzoic acid 

Downstream Products

• 1616599-03-1 (±)-1-{5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}ethyl methanesulfonate 
• 1616599-04-2 (±)-2-(1-chloroethyl)-N-(2,4-dimethoxybenzyl)-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
• 1616599-02-0 (±)-1-{5-[(2,4-dimethoxybenzyl)amino]-7-methoxy[1,2,4]triazolo[1,5-c]quinazolin-2-yl}ethanol 

Relevant academic research and scientific papers

PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula A: (structurally represented) where "RG1", "RG2a", "RG4", "RG5", "MG1", "n" and "m" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as

PIPERAZINE-SUBSTITUTED 7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula (A), as defined herein, which have binding activity for an A2A-receptor and are believed to be useful for treatment or management of CNS diseases or conditions which can be treated or managed using compounds w